Skip to main content

Advertisement

Table 2 MiRNA expression in good versus poor responders

From: Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

  Good responders Poor responders RQ Good versus poor P value
Mean ddCt SE RQ Mean ddCt SE RQ
MiR-27b −0.98 0.77 1.98 −0.92 0.64 1.90 1.04 0.80
MiR-105 −1.04 2.80 2.05 0.57 3.15 0.68 3.01 0.21
MiR-155 −0.66 1.25 1.58 −0.19 0.89 1.14 1.39 0.24
MiR-346 0.32 1.52 0.80 0.57 1.14 0.67 1.19 0.60
MiR-181a −1.64 0.85 3.11 −1.27 0.75 2.42 1.29 0.21
MiR-19a −3.39 1.84 10.45 −2.82 1.55 7.04 1.48 0.35
MiR-200b −0.57 0.92 1.49 0.05 1.42 0.97 1.54 0.15
MiR-27a −2.10 0.98 4.27 −2.00 0.82 4.00 1.07 0.77
MiR-30a −0.81 0.86 1.75 −0.66 0.88 1.58 1.11 0.65
Let-7a −0.67 0.79 1.59 −0.39 0.70 1.31 1.21 0.30
MiR-21 −3.16 1.16 8.92 −2.75 0.79 6.75 1.32 0.26
MiR-96 −4.56 1.32 23.59 −3.81 1.40 14.04 1.68 0.13
MiR-143 −0.73 1.35 1.66 −1.76 1.55 3.38 0.49 0.07
MiR-217 −2.91 3.09 7.53 −1.64 3.10 3.12 2.41 0.30
MiR-133a 0.91 1.69 0.53 0.33 1.79 0.79 0.67 0.36
MiR-133b 0.98 1.74 0.51 0.39 2.23 0.76 0.67 0.41
MiR-19b −2.95 1.71 7.73 −2.45 1.37 5.45 1.42 0.37
  1. Abbreviations: SE = standard error, RQ = relative quotient.